Cardace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardace

Understanding Cardace

Cardace is a medication belonging to a group of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It contains the active ingredient ramipril. This medication is primarily utilized to manage certain conditions affecting the heart and blood vessels.

Mechanism of Action

To understand how Cardace works, it is helpful to look at how the body regulates blood pressure. The body produces a substance called angiotensin II, which causes blood vessels to narrow and stimulates the release of hormones that can increase blood pressure.

Cardace works by blocking the enzyme responsible for creating angiotensin II. By reducing the production of this substance, the medication allows the blood vessels to relax and widen. This process results in:

  • Lowering of blood pressure: Making it easier for blood to flow through the vessels.
  • Reduced workload on the heart: Decreasing the effort required by the heart to pump blood throughout the body.

Clinical Applications

Cardace is used in several clinical scenarios related to cardiovascular health. Its primary functions include the management of high blood pressure (hypertension) and the treatment of heart failure, a condition where the heart does not pump blood as effectively as it should.

Additionally, it may be used as a preventive measure for individuals who are at an increased risk of experiencing significant cardiovascular events, such as a heart attack or stroke, particularly those with underlying vascular disease or diabetes. In some instances, it is also prescribed following a heart attack to help improve survival and reduce the strain on the heart muscle.

What side effects are possible with Cardace?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and essential safety constraints of Cardace (Ramipril), strictly based on official government regulatory documents.

Adverse Reaction Classification

Adverse reactions are classified by both their Frequency (rate of occurrence) and the affected System-Organ Class (e.g., Nervous system, Gastrointestinal).

Frequency Category Examples of Documented Reactions
Common (1 in 100 to 1 in 10) Dry, irritating cough, headache, dizziness, fatigue, increased blood potassium (hyperkalemia).
Uncommon (1 in 1,000 to 1 in 100) Vertigo, mood changes, transient erectile dysfunction, nausea.
Rare (1 in 10,000 to 1 in 1,000) Tremor, cholestatic jaundice, serious skin reactions.

Serious Adverse Reactions (SARs)

Regulatory sources highlight specific, rare, but clinically significant risks, including Angioedema (rapid swelling of the face, tongue, or throat) and severe Anaphylactoid reactions. Rarer serious events documented include Hepatic Failure and severe Blood Disorders (e.g., agranulocytosis).

Population-Specific Safety Constraints

The medicine is subject to explicit regulatory restrictions for certain patient groups:

  • Pregnancy: Ramipril is contraindicated during the second and third trimesters due to documented risk of serious foetal injury or death. Discontinuation is mandated upon detection of pregnancy.
  • Renal/Hepatic Impairment: Requires careful monitoring of kidney function and potassium levels. Use is contraindicated in cases of severe hepatic impairment or certain severe kidney conditions (e.g., bilateral renal artery stenosis).

High-Level Safety Restrictions

Cardace is contraindicated in patients with a history of angioedema related to a previous ACE inhibitor or certain hereditary forms of angioedema. Routine monitoring of serum potassium and renal function (creatinine) is mandated throughout treatment, as explicitly required by regulatory labels.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Cardace (Ramipril) based on the physiological consequences of excessive exposure. The most likely clinical signs and manifestations are related to severe blood pressure reduction, which can lead to cardiovascular instability.

Documented Overdose Manifestations

Feature Official Regulatory Description
Primary Manifestation Symptoms attributable to hypotension (low blood pressure) are the most likely clinical signs of overdosage with Ramipril.
Severe Outcome Risk Profound symptomatic hypotension is the primary concern, carrying the risk of significant cardiovascular compromise and requiring urgent response.

Emergency Action and Management

In the event of a suspected or confirmed overdosage, immediate medical attention is required to manage the serious cardiovascular risks associated with severe hypotension. The mandated treatment approach is defined as symptomatic and supportive.

Since no specific antidote is widely available for Ramipril overdosage, the focus of emergency care is stabilizing the patient's blood pressure. Treatment commonly involves the infusion of normal saline solution to correct volume depletion and maintain systemic blood pressure. Furthermore, regulatory context notes that laboratory determinations of the drug's concentration levels in the body have no established role in guiding the immediate clinical management of the overdose situation. The need for urgent help is based entirely on the potential for life-threatening blood pressure instability.

Therapeutic Uses of Cardace

What Cardace Treats: Main Uses and Benefits

Cardace (Ramipril) is commonly used across key cardiovascular and renal therapeutic areas.

The medication is generally used for managing sustained high blood pressure, providing prophylactic therapeutic support for high-risk patients, and acting as a supportive treatment for heart failure and kidney strain. Specifically, it assists in managing the risk of major cardiovascular events, such as heart attack or stroke, and is relevant for managing the symptoms of kidney strain, such as proteinuria, particularly in diabetic patients. This supportive use helps patients in managing conditions involving episodic or fluctuating manifestations of chronic complications.

“It is commonly used when symptoms are driven by systemic imbalance and the overall goal is supporting long-term stability.”

Quick Fact: Relief for Vascular Strain

Cardace is commonly used to help achieve and maintain lower blood pressure levels, supporting the easing of the heart's workload and contributing to assisting with managing symptoms related to organ-specific functional stress associated with high pressure.

Eligibility and Restrictions for Use

Cardace (Ramipril) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose eligibility is strictly defined by regulatory documents. Contraindications prohibit its use in several key populations:

  • Patients with a history of angioedema related to any ACE inhibitor or Angiotensin II Receptor Antagonist (AIIRA).
  • Women who are pregnant, especially during the second and third trimesters, or who are breastfeeding.
  • Patients taking sacubitril/valsartan or specific combinations of aliskiren (in diabetic or renally impaired patients) due to increased risk of severe adverse effects.
  • Individuals with haemodynamically relevant renal artery stenosis or those in hypotensive/unstable states.

Restricted or Limited Use applies to specific groups:

Population Regulatory Restriction
Pediatric Patients (<18) Use is not recommended; safety and efficacy are not established.
Renal Impairment Dosage must be adjusted based on creatinine clearance; use is not recommended in severe impairment (e.g., CrCl < 20-30 mL/min).
Hepatic Impairment Treatment requires close medical supervision and a maximum daily dose limit (e.g., 2.5 mg).

Eligibility is conditional upon the absence of these prohibitions and adherence to specified monitoring protocols for restricted-use populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cardace (Ramipril) interacts with several medicinal product classes and specific substances, as documented in official government labeling. These interactions primarily involve pharmacodynamic effects and specific prohibitions.

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is strictly prohibited. Initiation of Ramipril must not occur until a 36-hour waiting period has passed since the last dose of the neprilysin inhibitor. Use with Aliskiren is contraindicated in patients with Diabetes Mellitus or documented Renal Impairment (GFR less than 60 mL/min/1.73 m^2). Furthermore, the regulatory label prohibits Cardace use during certain extracorporeal treatments, such as high-flux membrane hemodialysis, due to the risk of severe reactions.

Pharmacodynamic and Exposure Interactions

Co-administration with agents that increase serum potassium, including potassium-sparing diuretics (e.g., Spironolactone, Triamterene) and potassium supplements, poses an additive risk of hyperkalemia. Combining Cardace with other antihypertensive agents or alcohol may result in an additive hypotensive effect. Official documentation also states that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure lowering effect and increase the risk of renal deterioration. Concomitant use with Lithium is documented to increase serum concentrations of Lithium, raising the risk of toxicity.

Mechanism of Action

The active substance in Cardace is ramipril, a prodrug that is converted in the liver to its active metabolite, ramiprilat.

Ramiprilat acts as a competitive inhibitor of the zinc metalloprotease enzyme, Angiotensin-Converting Enzyme (ACE), which is also known as kininase II. ACE is a pivotal component of the Renin-Angiotensin-Aldosterone System (RAAS), located on the endothelial surfaces of numerous tissues, particularly the lungs. This enzymatic inhibition prevents the cleavage of the decapeptide Angiotensin I to form the potent vasoconstrictor and trophic agent, Angiotensin II.

The resulting reduction in circulating and tissue Angiotensin II concentration leads to two primary molecular consequences: first, decreased Type 1 Angiotensin II Receptor ( AT1) activation on vascular smooth muscle, causing vasodilation and a reduction in systemic vascular resistance. Second, it reduces Angiotensin II-mediated stimulation of the adrenal cortex, which leads to a decrease in aldosterone secretion. Reduced aldosterone levels consequently decrease sodium and water reabsorption in the renal tubules, promoting natriuresis and diuresis. Ramiprilat's inhibition of ACE also slows the breakdown of the vasodilator peptide, bradykinin, which may contribute to the overall vasodilatory effect. These intracellular and systemic cascades collectively modulate systemic hemodynamics.

Dosage and Administration Information

How Cardace is Used: Official Administration Guidelines

Cardace (Ramipril) is administered orally in the form of a capsule or tablet, available in strengths including 1.25 mg, 2.5 mg, 5 mg, and 10 mg.


Standard Dosing and Frequency

Treatment is typically initiated at a low dose and gradually adjusted (titrated) to an effective maintenance level. The standard frequency is once daily, although twice-daily dosing may be necessary for specific conditions or if the effect wears off before the next dose.

Indication Initial Dose Maximum Daily Dose (Typical)
Hypertension 2.5 mg once daily 10 mg to 20 mg
Cardiovascular Risk Reduction 2.5 mg once daily 10 mg
Post-MI Heart Failure 2.5 mg twice daily 10 mg

Administration and Special Conditions

Cardace can be taken with or without food as food intake does not significantly affect its absorption. The tablets or capsules must be swallowed whole and must not be crushed or chewed when taken in their solid form.

If the capsule cannot be swallowed whole, its contents can be mixed with a small amount of applesauce, water, or apple juice and must be consumed entirely. For patients with renal or hepatic impairment, the initial dose is generally lower (1.25 mg) and the maximum daily dose is restricted (e.g., 5 mg for severe renal impairment), requiring close medical supervision.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardace (Ramipril)

The research into Cardace (Ramipril) consists primarily of large-scale Randomized Controlled Trials (RCTs). These types of studies are often used to compare a drug against a placebo (an inactive substance) or another medicine to understand patterns related to major, long-term health outcomes. Research provides context by describing group patterns, consistent with studies observing responses over defined time intervals.


Evidence for Cardiovascular Event Risk Reduction

Research exploring this area included large, multi-year randomized controlled trials involving thousands of high-risk patients, typically aged 55 or older, who already had established vascular disease or diabetes plus at least one other risk factor. Researchers monitored these populations for a mean period of around 4.5 years. The key measured outcomes were the occurrence of a composite major clinical event, such as myocardial infarction (heart attack), stroke, or cardiovascular death.

Research data show patterns related to the composite major clinical events, with a lower observed rate in the group receiving Ramipril compared to the placebo group. Researchers monitored the occurrence of stroke and heart attack and studies reported how symptoms evolved in the observed populations, with a lower observed frequency in the Ramipril group. The patterns observed was associated with a measured change in blood pressure that was observed in some studies to be modest.


Evidence for Heart Failure Following Myocardial Infarction

A major randomized controlled trial was evaluated in patients who had a heart attack and then showed clinical evidence of heart failure in the days immediately following the event. The primary outcome of all-cause death findings describe patterns observed in the studies, with a lower reported rate in the group receiving Ramipril over the study period. Some trials research examined progression to severe resistant heart failure, and a lower rate was observed in some studies in the group receiving Ramipril. Additionally, comparative evidence is lacking for major outcomes against some newer treatments that have been introduced for this specific condition since the original studies were conducted.


Evidence for Diabetic and Non-Diabetic Kidney Strain

Studies was evaluated in patient groups with Type 1 or Type 2 diabetes who showed signs of proteinuria (elevated protein in the urine, indicating kidney strain). The research explored outcomes related to systemic or functional imbalance, primarily the rate at which microalbuminuria progressed to overt proteinuria. Findings describe patterns where the use of Ramipril was associated with a lower rate of progression to overt nephropathy in the Ramipril group compared to the placebo group. Data for certain groups remain insufficient, particularly for patients with already severe renal impairment.

Key Studies & References

  1. Longterm survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure (AIRE-S study follow-up)

Frequently Asked Questions (FAQ)

Common questions about Cardace (FAQ)


Q: How long does it take for Cardace to start working?

According to official product information, the active form of Cardace, called ramiprilat, is generally detectable in the bloodstream within one hour after taking a dose. The amount of ramiprilat typically reaches its peak concentration in the blood within two to four hours.


Q: When will the full effect of Cardace be noticeable?

For managing high blood pressure, the drug's initial effect begins one to two hours after administration, with the maximum effect seen within three to six hours.

However, official information notes that achieving the full, consistent therapeutic benefit may require several weeks of continuous therapy.


Q: Is Cardace considered a blood thinner?

No, Cardace is not classified as a blood thinner (anticoagulant or antiplatelet agent). It belongs to the Angiotensin-Converting Enzyme (ACE) Inhibitor class, and its primary action is to widen blood vessels to help lower blood pressure.


Q: Why do some people experience a persistent dry cough with Cardace?

Official documents explain that Cardace works by inhibiting an enzyme that also helps break down a substance called bradykinin. The potential for the accumulation of bradykinin in the lungs is cited in official documents as a mechanism believed to contribute to the common dry cough.


Q: Is the cough from Cardace a serious side effect?

Regulatory documents list the dry, irritative cough as a common side effect, meaning it is seen in more than 1 in 100 people.

Regulatory documents list it as a 'common' side effect, which is distinct from the 'rare' category where serious adverse reactions like angioedema are classified.


Q: Does taking Cardace require any special dietary restrictions?

The regulatory label does not strictly mandate special dietary restrictions. However, the label does document a risk of high potassium (hyperkalemia) when the drug is used with potassium supplements or certain diuretics.

This specific interaction risk is noted in regulatory information as a factor that may require caution regarding diet.


Q: Are there any specific foods to avoid while on Cardace?

No specific food items are forbidden in official information. However, due to the documented risk of increased blood potassium levels, official patient information often cautions against using salt substitutes that contain potassium.


Q: What happens if I miss a dose of Cardace?

Official guidance describes that a missed dose may be taken as soon as it is remembered. If it is close to the time for the next scheduled dose, the information suggests skipping the missed dose and resuming the regular schedule.


Q: What should I do if I accidentally take too much Cardace?

Overdose information states that the most likely sign of taking too much Cardace is severe hypotension, which means dangerously low blood pressure. If an overdose is suspected, emergency medical services should be contacted immediately, as outlined in patient safety information.


Q: Can Cardace affect blood sugar levels, especially for people with diabetes?

Adverse event listings found in regulatory documents include reported metabolic changes. Specifically, a decrease in blood glucose levels has been listed as an undesirable effect, which may be relevant for people with diabetes.


Q: Is Cardace safe to use for people with pre-existing kidney problems?

Regulatory documents indicate that use in patients with pre-existing kidney problems requires dose adjustment and close monitoring of kidney function. The drug is strictly prohibited (contraindicated) for use in patients with severe kidney impairment or specific conditions like bilateral renal artery stenosis.


Q: Does Cardace help protect the kidneys or can it harm them?

Research studies have indicated patterns associated with a reduced rate of kidney disease progression in certain patients with diabetes. However, regulatory warnings also note that the drug can cause renal impairment, and routine monitoring of kidney function is required throughout treatment.


Q: Is Cardace recommended for long-term use?

The drug's authorization is supported by large-scale clinical trials that studied cardiovascular outcomes over a mean period of approximately 4.5 years. This research evidence is consistent with the drug's use for chronic cardiovascular conditions.


Q: Can elderly patients use Cardace?

Official documents specify that the drug can be used by elderly patients (65 years and older). However, the starting dose is often lower, and dosage adjustments are slower, reflecting the need for cautious use and monitoring in this population.


Q: Does Cardace cause changes in vision?

Regulatory documents list visual disturbances, including blurred vision, as an uncommon undesirable effect. This means it is reported to affect fewer than 1 in 100 people.


Q: Is Cardace considered habit-forming or addictive?

Official regulatory documents state that Ramipril has no documented potential for drug abuse or dependency. No reports of habit-forming behavior have been identified in official sources.


Q: Can Cardace be taken with other blood pressure medicines?

Yes, Cardace can be taken in combination with other blood pressure-lowering agents. However, official documents warn that this combination may result in an additive hypotensive effect, which is an excessive drop in blood pressure that requires monitoring.


Q: Why is blood pressure and kidney function checked regularly when taking Cardace?

Routine monitoring is explicitly required by regulatory documents to check for two main risks. These include ensuring the drug is not causing an excessive drop in blood pressure (hypotension) and monitoring for the potential risks of kidney deterioration and high potassium levels (hyperkalemia).


Q: Is it necessary to stop taking Cardace before surgery or dental procedures?

Official documents caution that the use of Cardace can cause a drop in blood pressure during surgery or anesthesia. This necessitates discussion with the healthcare team to determine if adjustment or temporary withholding of the treatment is required prior to such procedures.


Q: Can Cardace interact with herbal supplements?

Official patient information generally emphasizes that the healthcare team should be aware of all products, including herbal supplements, due to the risk of unknown or undocumented interactions.


Q: Does Cardace affect a person's ability to drive or operate machinery?

Regulatory documents note that the drug may cause side effects such as dizziness or fatigue. These effects could potentially impair a person's ability to drive or operate heavy machinery, especially when first starting treatment or changing doses.


Q: Is Cardace ever prescribed in combination with a water pill (diuretic)?

Yes, Cardace is commonly used in combination with diuretics for high blood pressure. However, combination with certain potassium-sparing diuretics carries a specific, increased risk of hyperkalemia (high potassium).


Q: Do different strengths of Cardace tablets have different uses?

The drug is available in various strengths (e.g., 1.25 mg, 5 mg) primarily to accommodate the wide range of required initial, maintenance, and maximum doses.

These doses vary depending on the specific condition being treated and the patient's individual factors, such as kidney function.


Q: Do official documents mention whether Ramipril works differently for different ethnic groups?

Official drug labels include data on pharmacokinetics in special populations. Documents note that the blood pressure response to this class of medication may be less pronounced in Black patients when used as a monotherapy (without a diuretic).


Q: Can taking Cardace lead to low blood pressure symptoms like fainting?

Regulatory warnings list severe hypotension (very low blood pressure) and related symptoms, including fainting (syncope), as potential risks. This risk is noted to be higher in patients who are dehydrated or have severe heart failure.


Q: Why is Cardace sometimes started at a very low dose?

The starting dose is explicitly kept low and gradually increased (titrated) as noted in official guidance. This is done to minimize the risk of a rapid, excessive drop in blood pressure (hypotension) and associated adverse effects like dizziness.


Q: Can Cardace be used by people who have recently been dehydrated?

Regulatory documents include a specific warning regarding patients who are volume- or salt-depleted (e.g., due to diuretic therapy, vomiting, or diarrhea).

In these individuals, the drug can cause a sharp drop in blood pressure, known as symptomatic hypotension.


Q: Is Cardace a long-acting medicine?

The drug is typically dosed once daily because the half-life of its active metabolite, ramiprilat, is between 13 to 17 hours. This half-life allows the drug to provide continuous 24-hour therapeutic coverage.

How should Cardace be stored and disposed of?

How to Store and Dispose of Cardace?

Official regulatory documents define strict environmental and containment rules to maintain the product's stability and ensure safety.

Requirement Type Official Regulatory Statement
Storage Temperature Store at controlled room temperature, typically 15 C–30 C (59 F–86 F). Do not refrigerate or freeze.
Container & Protection Keep in the original package and store in a tightly closed, well-closed container with a safety closure. Protect from excess heat and moisture.
Child Safety The product must be stored out of the sight and reach of children and should be stored locked up due to the required safety closure.
Disposal Compliance Avoid release to the environment; do not dispose of the product by throwing it into household waste or wastewater. Local regulations must be followed for discarding unused or expired medicine.

These constraints ensure the chemical integrity of the Ramipril capsule is preserved for its defined shelf-life and govern that the final disposition prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardace found in:

A-Z Index: